Tortus AI vs Bristol Myers Squibb

Side-by-side comparison of AI visibility scores, market position, and capabilities

Bristol Myers Squibb leads in AI visibility (80 vs 35)
Tortus AI logo

Tortus AI

EmergingHealthcare

AI Clinical Documentation

Tortus AI provides an AI agent that sits alongside clinicians during patient visits, automatically generating clinical notes and handling documentation tasks in real time.

AI VisibilityBeta
Overall Score
D35
Category Rank
#551 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
32
Perplexity
29
Gemini
38

About

Tortus AI is a healthcare AI company founded in 2022 in London that develops an AI agent designed to reduce the documentation burden on physicians and clinical staff. The platform operates as a persistent AI presence during clinical encounters, listening to patient-clinician conversations and automatically generating structured clinical notes, coding suggestions, referral letters, and other administrative documentation. Unlike simple transcription tools, Tortus AI interprets clinical context to generate documentation that conforms to specialty-specific formats and coding requirements. The company serves NHS trusts and private healthcare organizations in the United Kingdom and is expanding internationally. Physician burnout driven by excessive documentation requirements is a critical healthcare workforce crisis, with doctors spending roughly half their working time on administrative tasks rather than patient care. Tortus AI addresses this directly by taking over documentation workflows and allowing clinicians to focus on clinical reasoning and patient relationships. The company raised $12M and has deployed across multiple clinical specialties including primary care, emergency medicine, and outpatient specialties with strong clinician satisfaction rates.

Full profile
Bristol Myers Squibb logo

Bristol Myers Squibb

LeaderHealthcare Tech

Enterprise

Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.

AI VisibilityBeta
Overall Score
A80
Category Rank
#18 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
78
Gemini
80

About

Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).

Full profile

AI Visibility Head-to-Head

35
Overall Score
80
#551
Category Rank
#18
78
AI Consensus
83
stable
Trend
stable
32
ChatGPT
78
29
Perplexity
78
38
Gemini
80
30
Claude
84
34
Grok
77

Key Details

Category
AI Clinical Documentation
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Tortus AI
AI Clinical Documentation

Integrations

Only Bristol Myers Squibb
Bristol Myers Squibb is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.